1173199-23-9

Upstream product

• 824-80-6 sodium 4-fluorobenzenesulfinate 
• 36404-88-3 2-chloro-3-carbaldehydepyridine 
• 399-72-4 5-fluoro-2-methyl-1H-indole 
• 851460-85-0 (5-fluoro-2-methylindol-1-yl)-acetic acid ethyl ester 
• 1140506-56-4 2-(4-fluorobenzenesulfonyl)pyridine-3-carboxaldehyde 

Downstream Products

• 1155694-18-0 [5-fluoro-3-({2-[(4-fluorobenzene)sulfonyl]pyridin-3-yl}methyl)-2-methylindol-1-yl]acetic acid 

Relevant academic research and scientific papers

PROCESS FOR THE PREPARATION OF 3-SUBSTITUTED (INDOL-1-YL)-ACETIC ACID ESTERS

The invention relates to an industrial scale process for the preparation of a compound of general formula (I): (Formula (I)) wherein R1, R2and R3are as defined herein. The process comprises reacting compounds of general fo

POLYMORPHIC FORM OF [5-FLUORO-3-({2-[(4-FLUOROBENZENE) SULFONYL]PYRIDIN-3-YL}METHYL)-2-METHYLINDOL-1-YL]-ACETIC ACID

The invention relates to a polymorphic form of [5-fluoro-3-({2-[(4- fluorobenzene)sulfonyl]pyridin-3-yl}methyl)-2-methylindol-1-yl]-acetic acid and is therefore useful for preparing stable pharmaceutical formulations.

Compounds Having CRTH2 Antagonist Activity

Compounds of general formula (I) wherein W is chloro or fluoro;R1 is phenyl optionally substituted with one or more substituents selected from halo, —CN, —C1-C6 alkyl, —SOR3, —SO2R3, —SO2N(R2)2, —N(R2)2, —NR2C(O)R3, —CO2R2, —CONR2R3, —NO2, —OR2, —SR2, —O(CH2)pOR2, and —O(CH2)p—O—(CH2)qOR2 wherein each R2 is independently hydrogen, —C1-C6 alkyl, —C3-C8 cycloalkyl, aryl or heteroaryl;each R3 is independently, —C1-C6 alkyl, —C3-C8 cycloalkyl, aryl or heteroaryl;p and q are each independently an integer from 1 to 3; and their pharmaceutically acceptable salts, hydrates, solvates, complexes or prodrugs are useful in orally administrable compositions for the treatment of allergic diseases such as asthma, allergic rhinitis and atopic dermatitis.

COMPOUNDS HAVING CRTH2 ANTAGONIST ACTIVITY

Compounds of general formula (I) wherein W is chloro or fluoro; R1 is phenyl optionally substituted with one or more substituents selected from halo, -CN, -C1-C6 alkyl, -SOR3, -SO2R3, -SO2N(R2)2, -N(R2)2, -NR2C(O)R3, -CO2R2, - CONR2R3, -NO2, -OR2, -SR2, -O(CH2)POR2, and -O(CH2)pO(CH2)qOR2 wherein each R2 is independently hydrogen, -C1-C6 alkyl, -C3-C8 cycloalkyl, aryl or heteroaryl; each R3is independently, -C1-C6 alkyl, -C3-C8 cycloalkyl, aryl or heteroaryl; p and q are each independently an integer from 1 to 3; and their pharmaceutically acceptable salts, hydrates, solvates, complexes or prodrugs are useful in orally administrable compositions for the treatment of allergic diseases such as asthma, allergic rhinitis and atopic dermatitis.